Développement des greffes haplo-identiques chez l'adulte atteint d'une hémopathie maligne

Translated title of the contribution: Advances in haploidentical transplantation in hematological malignancies

Luca Castagna, Didier Blaise

Research output: Contribution to journalArticle

Abstract

The possibility to use a family donor sharing only one haplotype with recipient affected by hematological malignancy has been searched from many years because it allows having a donor in every case for every patient. At the beginning, this kind of transplantation was considered too toxic, but after the development of specific strategies of conditioning regimens and ex vivo T-cell depletion, its feasibility and efficacy has been proved, mainly for acute leukemia. However, these haploidentical programs with ex vivo T-cell depletion need of sophisticated and dedicated laboratories and are characterized by frequent infectious complications and relapse, because of delayed immune reconstitution. For these reasons, many groups have developed alternative program for haploidentical transplantation, without ex vivo T-cell depletion, obtaining encouraging results in haematological malignancies. In this review, we analyze data produced by different groups, underscoring their principal characteristics.

Original languageFrench
Pages (from-to)1141-1151
Number of pages11
JournalBulletin du Cancer
Volume99
Issue number12
DOIs
Publication statusPublished - Dec 2012

Fingerprint

Hematologic Neoplasms
Transplantation
T-Lymphocytes
Tissue Donors
Poisons
Haplotypes
Leukemia
Recurrence

Keywords

  • Haploidentical transplantation
  • Hematological malignancies
  • Myeloablative conditioning regimens
  • Reduced intensity conditioning regimens

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging
  • Hematology

Cite this

Développement des greffes haplo-identiques chez l'adulte atteint d'une hémopathie maligne. / Castagna, Luca; Blaise, Didier.

In: Bulletin du Cancer, Vol. 99, No. 12, 12.2012, p. 1141-1151.

Research output: Contribution to journalArticle

@article{b356f1f9228a43af9fcb89e6be68ed79,
title = "D{\'e}veloppement des greffes haplo-identiques chez l'adulte atteint d'une h{\'e}mopathie maligne",
abstract = "The possibility to use a family donor sharing only one haplotype with recipient affected by hematological malignancy has been searched from many years because it allows having a donor in every case for every patient. At the beginning, this kind of transplantation was considered too toxic, but after the development of specific strategies of conditioning regimens and ex vivo T-cell depletion, its feasibility and efficacy has been proved, mainly for acute leukemia. However, these haploidentical programs with ex vivo T-cell depletion need of sophisticated and dedicated laboratories and are characterized by frequent infectious complications and relapse, because of delayed immune reconstitution. For these reasons, many groups have developed alternative program for haploidentical transplantation, without ex vivo T-cell depletion, obtaining encouraging results in haematological malignancies. In this review, we analyze data produced by different groups, underscoring their principal characteristics.",
keywords = "Haploidentical transplantation, Hematological malignancies, Myeloablative conditioning regimens, Reduced intensity conditioning regimens",
author = "Luca Castagna and Didier Blaise",
year = "2012",
month = "12",
doi = "10.1684/bdc.2012.1665",
language = "Francese",
volume = "99",
pages = "1141--1151",
journal = "Bulletin du Cancer",
issn = "0007-4551",
publisher = "John Libbey Eurotext",
number = "12",

}

TY - JOUR

T1 - Développement des greffes haplo-identiques chez l'adulte atteint d'une hémopathie maligne

AU - Castagna, Luca

AU - Blaise, Didier

PY - 2012/12

Y1 - 2012/12

N2 - The possibility to use a family donor sharing only one haplotype with recipient affected by hematological malignancy has been searched from many years because it allows having a donor in every case for every patient. At the beginning, this kind of transplantation was considered too toxic, but after the development of specific strategies of conditioning regimens and ex vivo T-cell depletion, its feasibility and efficacy has been proved, mainly for acute leukemia. However, these haploidentical programs with ex vivo T-cell depletion need of sophisticated and dedicated laboratories and are characterized by frequent infectious complications and relapse, because of delayed immune reconstitution. For these reasons, many groups have developed alternative program for haploidentical transplantation, without ex vivo T-cell depletion, obtaining encouraging results in haematological malignancies. In this review, we analyze data produced by different groups, underscoring their principal characteristics.

AB - The possibility to use a family donor sharing only one haplotype with recipient affected by hematological malignancy has been searched from many years because it allows having a donor in every case for every patient. At the beginning, this kind of transplantation was considered too toxic, but after the development of specific strategies of conditioning regimens and ex vivo T-cell depletion, its feasibility and efficacy has been proved, mainly for acute leukemia. However, these haploidentical programs with ex vivo T-cell depletion need of sophisticated and dedicated laboratories and are characterized by frequent infectious complications and relapse, because of delayed immune reconstitution. For these reasons, many groups have developed alternative program for haploidentical transplantation, without ex vivo T-cell depletion, obtaining encouraging results in haematological malignancies. In this review, we analyze data produced by different groups, underscoring their principal characteristics.

KW - Haploidentical transplantation

KW - Hematological malignancies

KW - Myeloablative conditioning regimens

KW - Reduced intensity conditioning regimens

UR - http://www.scopus.com/inward/record.url?scp=84872362240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872362240&partnerID=8YFLogxK

U2 - 10.1684/bdc.2012.1665

DO - 10.1684/bdc.2012.1665

M3 - Articolo

C2 - 23220039

AN - SCOPUS:84872362240

VL - 99

SP - 1141

EP - 1151

JO - Bulletin du Cancer

JF - Bulletin du Cancer

SN - 0007-4551

IS - 12

ER -